In Cannabis Pharmacy, expert Michael Backes offers evidence-based information on using cannabis to treat an array of ailments and conditions. He provides information on how cannabis works with the body´s own system, how best to prepare and administer it, and how to modify and control dosage. This newly revised edition is now completely up-to-date with the latest information on the body´s encannabinoid system, which is now understood to control emotion, appetite, and memory, delivery and dosing of cannabis, including e-cigarette designs, additional varietals, and a new system for classification, as well as 21 additional ailments and conditions that can be treated with medical marijuana. There are currently more than 4.2 million medical cannabis patients in the United States, and there are 25 states plus the District of Columbia where medical cannabis is legal
In Cannabis Pharmacy, expert Michael Backes offers evidence-based information on using cannabis to treat an array of ailments and conditions. He provides information on how cannabis works with the body´s own system, how best to prepare and administer it, and how to modify and control dosage. This newly revised edition is now completely up-to-date with the latest information on the body´s encannabinoid system, which is now understood to control emotion, appetite, and memory, delivery and dosing of cannabis, including e-cigarette designs, additional varietals, and a new system for classification, as well as 21 additional ailments and conditions that can be treated with medical marijuana. There are currently more than 4.2 million medical cannabis patients in the United States, and there are 29 states plus the District of Columbia where medical cannabis is legal.
Cannabis Pharmacy:The Practical Guide to Medical Marijuana Michael Backes
Cannabis Pharmacy:The Practical Guide to Medical Marijuana -- Revised and Updated Michael Backes
This book highlights current Cannabis research: its botany, authentication, biotechnology, in vitro propagation, chemistry, cannabinoids biosynthesis, metabolomics, genomics, biomass production, quality control, and pharmacology. Cannabis sativa L. (Family: Cannabaceae) is one of the oldest sources of fiber, food and medicine. This plant has been of interest to researchers, general public and media not only due to its medicinal properties but also the controversy surrounding its illicit use. Cannabis has a long history of medicinal use in the Middle East and Asia, being first introduced as a medicine in Western Europe in the early 19 th century. Due to its numerous natural constituents, Cannabis is considered a chemically complex species. It contains a unique class of terpeno-phenolic compounds (cannabinoids or phytocannabinoids), which have been extensively studied since the discovery of the chemical structure of tetrah ydrocannabinol (? 9 -THC), commonly known as THC, the main constituent responsible for the plants psychoactive effects. An additionally important cannabinoid of current interest is Cannabidiol (CBD). There has been a significant interest in CBD and CBD oil (extract of CBD rich Cannabis) over the last few years because of its reported activity as an antiepileptic agent, particularly its potential use in the treatment of intractable epilepsy in children. Suman Chandra , Ph.D. Senior Research Scientist National Center for Natural Products Research Research School of Pharmaceutical Sciences School of Pharmacy The University of Mississippi, USA Hemant Lata , Ph.D. Senior Research Scientist National Center for Natural Products Research Research School of Pharmaceutical Sciences School of Pharmacy The University of Mississippi, USA Mahmoud A. ElSohly , Ph.D. Research Professor National Center for Natural Products Research& Research School of Pharmaceutical Sciences School of Pharmacy The University of Mississippi, USA & ElSohly Laboratories Inc. Oxford, Mississippi, USA
The science of cannabinoids is 50 years old. These past years provided a remarkable and constant number of breakthroughs, showing that the signaling mediated by endocannabinoids and lipid mediators impacts almost every function of the body. Indeed, this represents a special field of research, which allows tackling the complexity of biological functions, and provides potential therapeutic frameworks for a plethora of diseases. The number of exciting discoveries brought up to the scientific community almost on a daily basis highlights the importance of an updated volume on this topic. Particularly, given that potential therapeutic benefits of cannabis and cannabinoids are currently under heavy analysis in many Countries worldwide. Hence, the main objective of this book is to explore not only some of the many functions of endocannabinoids (and lipid mediators) in physiological control of networks at a cellular and molecular level, but also to extend this knowledge for potential use of cannabinoids and/or drugs regulating endocannabinoid levels in vivo as therapeutic target(s) in neurological and neuropsychiatric disorders. In this book new findings and ideas about the endocannabinoid system and its roles as neuronal circuit modulator related to human brain pathologies characterized by alterations in neuroplasticity will be highlighted. Endocannabinoid roles in key systems controlling appetite, pain, learning and memory, as well as sleep and stress responses will be presented. In addition, pathological processes associated with changes in endocannabinoid signaling will be discussed in the context of anxiety, autism, depression and addiction. This book will provide an excellent background to researchers looking for extending their areas of interest, and to newcomers in the field. Miriam Melis is an Associate Professor at the University of Cagliari, Italy. She holds a PharmD in Pharmacy (University of Palermo, 1993) as well as a PhD in Neuroscience University of Cagliari, 2011). During her career Miriam Melis worked as a Research Fellow for two years at the Ernest Gallo Clinic and Research Center, San Francisco, CA, US and as a Visiting Scientist at Lund Universitet Wallenberg Neuroscience Center in 2011. Her current research is focused on understanding neurobiological underpinnings (e.g., adaptations of both mesocorticolimbic dopamine pathway and endocannabinoid system) of resilience and susceptibility to neuropsychiatric disorders (e.g., substance use disorder, antisocial behavior, anxiety, depression). Her group discovered that dopamine neurons can synthesize and release lipid signaling molecules (i.e. endocannabinoids and their cognate molecules) under both physiological and pathological conditions. She has published 34 research papers as well as 2 book chapters on this topic.
A volume in the Emerging Issues in Analytical Chemistry series, Analytical Assessment of E-Cigarettes: From Contents to Chemical and Particle Exposure Profiles addresses the many issues surrounding electronic cigarettes in an unprecedented level of scientific detail. The plethora of product devices, formulations, and flavors, combined with the lack of industry standards and labeling requirements, quality control, and limited product oversight, has given rise to public concern about initiation of use and potential for adverse exposure and negative long-term health outcomes. This volume discusses how analytical methods can address these issues and support the manufacturing, labeling, distribution, testing, regulation, and monitoring for consistency of products with known chemical content and demonstrated performance characteristics. The book begins with the background on aerosol drug delivery services and e-cigarettes, constituents of nicotine-containing liquid dosing formulations, typical use scenarios and associated aerosol emissions, and chemical exposures and pharmacological and toxicological effect profiles, and then continues with descriptions of the analytical methods used to characterize the chemicals in formulations and emissions from e-cigarettes, including their stability, physical particle-size distribution and thermal degradation under commonly employed conditions of use. Analytical methods enabling detection of biomarkers of exposure and harm in complex biological matrices are discussed, with an emphasis on constituents or emissions of current medicinal interest or with potential to produce harm. Opportunities and challenges for analytical chemistry in supporting the continued development and use of safe and consistent dosage formulations as alternatives to tobacco products are also explored, with a concluding section describing an analytical approach to a risk-benefit assessment of e-cigarette use on human health. The Emerging Issues in Analytical Chemistry series is published in partnership with RTI International and edited by Brian F. Thomas. Please be sure to check out our other featured volumes: Thomas, Brian F. and ElSohly, Mahmoud. The Analytical Chemistry of Cannabis: Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations , 9780128046463, December 2015. Hackney, Anthony C. Exercise, Sport, and Bioanalytical Chemistry: Principles and Practice , 9780128092064, March 2016. Tanna, Sangeeta and Lawson, Graham. Analytical Chemistry for Assessing Medication Adherence , 9780128054635, April 2016. Rao, Vikram; Knight, Rob; and Stoner, Brian. Sustainable Shale Oil and Gas: Analytical Chemistry, Biochemistry, and Geochemistry Methods , 9780128103890, September 2016. Discusses the chemistry and physics involved in aerosol production, inhalation, deposition, chemical exposure, and effect assessment Contains current information and state-of-the-science methods on e-cigarette emissions, exposures, and harm assessment Offers an authoritative, objective perspective from five of the most well-recognized scientists in their areas of expertise who have no personal stake in the e-cigarette industry or the opposition Includes a foreword written by Dr. Neal Benowitz Konstantinos E. Farsalinos, M.D., is a research fellow at the Onassis Cardiac Surgery Center in Athens, Greece, and at the Department of Pharmacy, University of Patras, Greece. He has been conducting laboratory and clinical research on e-cigarettes as a principal investigator since 2011. Examples of his work include the first study on the cytotoxic effects of e-cigarette vapor on cultured cells and the immediate effects of e-cigarette use on cardiac function and coronary circulation. He ran a worldwide online survey of almost 20,000 vapers (users of e-cigarettes) identifying patterns of use and experience with e-cigarettes among consumers, published in 2014. He has presented his research findings at major international scientific congresses and his research was used in preparing the regulatory framework on e-cigarettes by the European Union. As of 2016, he has published more than 40 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction, and e-cigarettes.